EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Shares in PharmaMar crashed after the Spanish biotech revealed a phase 3 ovarian cancer trial had missed its primary endpoint. Synthetic tetrahydroisoquinoline alkaloid Zepsyre failed to improve progression-free survival in patients with platinum-resistant ovarian cancer. Statement (PDF)

> Ablynx named Robert Friesen, Ph.D., as its CSO. Friesen joins from ProQR at a time when Ablynx is the subject of takeover interest from Novo Nordisk. Release

> BioCanCell unveiled plans to list its stock in the U.S. The Israeli biotech revealed its IPO intentions in a statement about the pricing of a $25 million (€20 million) financing round. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Advicenne followed up on its IPO by appointing Linda Law, M.D., to oversee its U.S. clinical trial activities. Release

> Genfit kicked off its pediatric NASH program. Statement

> ImmuPharma raised £10 million ($14 million). Release

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.